CADL Candel Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Candel Therapeutics Inc reported revenue of n/a, net income of −$38.9M and diluted EPS of −$0.52; for the fiscal year ended December 2025 revenue was n/a.
CADL annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$48.3M, net income −$38.2M (margin n/a), EPS −$0.72
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$33.4M, net income −$55.2M (margin n/a), EPS −$1.74
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$38.4M, net income −$37.9M (margin n/a), EPS −$1.31
- Fiscal year ended Dec 2022: revenue $125K, gross profit n/a, operating income −$34.7M, net income −$18.8M (margin -15035.2%), EPS −$0.65
- Fiscal year ended Dec 2021: revenue $125K, gross profit n/a, operating income −$25.7M, net income −$36.1M (margin -28899.2%), EPS −$1.91
CADL quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$38.9M, EPS −$0.52
- Quarter ended Mar 31, 2026: revenue n/a, net income −$8.86M, EPS −$0.14
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$29.5M, EPS −$0.55
- Quarter ended Sep 30, 2025: revenue n/a, net income −$11.3M, EPS −$0.21
- Quarter ended Jun 30, 2025: revenue n/a, net income −$4.80M, EPS −$0.09
- Quarter ended Mar 31, 2025: revenue n/a, net income $7.38M, EPS $0.13
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$14.1M, EPS −$0.39
- Quarter ended Sep 30, 2024: revenue n/a, net income −$10.6M, EPS −$0.33
- Quarter ended Jun 30, 2024: revenue n/a, net income −$22.2M, EPS −$0.74
- Quarter ended Mar 31, 2024: revenue n/a, net income −$8.22M, EPS −$0.28
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$11.1M, EPS −$0.39
- Quarter ended Sep 30, 2023: revenue n/a, net income −$8.44M, EPS −$0.29
- Quarter ended Jun 30, 2023: revenue n/a, net income −$9.61M, EPS −$0.33
- Quarter ended Mar 31, 2023: revenue n/a, net income −$8.80M, EPS −$0.30
- Quarter ended Dec 31, 2022 (from the annual report): revenue $32.0K (up 0.0% year over year), net income −$5.08M, EPS −$0.18
- Quarter ended Sep 30, 2022: revenue $31.0K (up 0.0% year over year), net income −$8.69M, EPS −$0.30
- Quarter ended Jun 30, 2022: revenue $31.0K (up 0.0% year over year), net income −$4.15M, EPS −$0.14
- Quarter ended Mar 31, 2022: revenue $31.0K (up 0.0% year over year), net income −$874K, EPS −$0.03
- Quarter ended Dec 31, 2021 (from the annual report): revenue $32.0K, net income $1.60M, EPS $0.62
- Quarter ended Sep 30, 2021: revenue $31.0K, net income −$16.2M, EPS −$0.69
CADL cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$38.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$27.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$34.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$31.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$22.2M, share buybacks n/a
CADL balance sheet
- Jun 30, 2026: cash $202M, total assets $208M, total liabilities $82.0M, shareholders' equity $126M
- Mar 31, 2026: cash $195M, total assets $202M, total liabilities $63.9M, shareholders' equity $138M
- Dec 31, 2025: cash $120M, total assets $125M, total liabilities $73.3M, shareholders' equity $51.9M
- Sep 30, 2025: cash $87.0M, total assets $93.6M, total liabilities $13.5M, shareholders' equity $80.1M
- Jun 30, 2025: cash $101M, total assets $106M, total liabilities $15.8M, shareholders' equity $90.2M
- Mar 31, 2025: cash $92.2M, total assets $95.9M, total liabilities $21.2M, shareholders' equity $74.7M
- Dec 31, 2024: cash $103M, total assets $107M, total liabilities $40.5M, shareholders' equity $66.3M, long-term debt $1.73M
- Sep 30, 2024: cash $16.6M, total assets $21.5M, total liabilities $36.8M, shareholders' equity −$15.3M, long-term debt $4.23M
Is CADL profitable?
No. Candel Therapeutics Inc lost $88.5M over the last four quarters.
What is CADL's EPS?
Diluted earnings per share over the last four quarters were −$1.42; −$0.52 in the latest quarter.